Conventus Orthopaedics completed a US $20MM equity financing. Funds will support commercialization of proximal humerus fracture repair technology and the development of the Conventus Cage™ intramedullary implant for extremity fracture repair. Deerfield Management led the financing.
The Nitinol-based Conventus Cage provides a rigid internal scaffold and expands within bone to inhibit collapse of a fracture. It is FDA-cleared for use in the shoulder, elbow and wrist fractures. At the end of 2016, the device had been used to treat >700 patients.
Conventus Orthopaedics completed a US $20MM equity financing. Funds will support commercialization of proximal humerus fracture repair technology and the development of the Conventus Cage™ intramedullary implant for extremity fracture repair. Deerfield Management led the financing.
The Nitinol-based Conventus Cage provides a rigid internal...
Conventus Orthopaedics completed a US $20MM equity financing. Funds will support commercialization of proximal humerus fracture repair technology and the development of the Conventus Cage™ intramedullary implant for extremity fracture repair. Deerfield Management led the financing.
The Nitinol-based Conventus Cage provides a rigid internal scaffold and expands within bone to inhibit collapse of a fracture. It is FDA-cleared for use in the shoulder, elbow and wrist fractures. At the end of 2016, the device had been used to treat >700 patients.
Copy to clipboard 
